Patents by Inventor Lars Bruce
Lars Bruce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10407514Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.Type: GrantFiled: November 10, 2015Date of Patent: September 10, 2019Assignee: TX MEDIC ABInventors: Lars Bruce, Ulf Brasen
-
Publication number: 20180298116Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.Type: ApplicationFiled: November 10, 2015Publication date: October 18, 2018Inventors: Lars BRUCE, Ulf BRASEN
-
Publication number: 20180221403Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.Type: ApplicationFiled: July 15, 2016Publication date: August 9, 2018Applicant: TX Medic ABInventors: Lars BRUCE, Adam BRUCE, Anders WAAS
-
Patent number: 9957311Abstract: Surface-binding peptides have the capability of binding to surfaces of biocompatible materials and can thereby be used to immobilize various heterologous molecules of interest onto the surface. This means that surfaces of, for instance, implants and implantable medical devices can be tailored to present various characteristics by immobilizing selected heterologous molecules of interest on the surfaces of the implants and implantable medical devices. The surface-binding peptides consist of 5-17 consecutive amino acids of an extended beta-hairpin motif EIIATMKKKGEKRCLNP (SEQ ID NO: 57) in Interferon gamma-induced protein 10 (IP-10).Type: GrantFiled: December 19, 2014Date of Patent: May 1, 2018Assignee: TIKOMED ABInventors: Lars Bruce, Staale Lyngstadaas
-
Publication number: 20170151275Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.Type: ApplicationFiled: June 11, 2015Publication date: June 1, 2017Inventors: Anders WAAS, Lars BRUCE, Adam BRUCE
-
Patent number: 9656015Abstract: A body fluid purifying arrangement comprises a purifying chamber having a fluid input and a fluid output, a first filter arranged in connection the fluid input, and a second filter arranged in connection with the fluid output. In another embodiment, a body fluid purifying arrangement in the form of a syringe comprises a purifying chamber having a common fluid input and fluid output, and a filter arranged in connection with the common fluid input and output. Granules or particles made of a metal or an oxide of a metal are retained within the purifying chamber by the respective filter(s) to purify a body fluid passing through the purifying chamber from 10 kDa interferon-? inducible protein, IP-10, wherein said metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.Type: GrantFiled: June 23, 2014Date of Patent: May 23, 2017Assignee: PROPHY MED ABInventors: Lars Bruce, Staale Petter Lyngstadaas
-
Patent number: 9649426Abstract: A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-? inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.Type: GrantFiled: June 23, 2014Date of Patent: May 16, 2017Assignee: PROPHY MED ABInventors: Lars Bruce, Staale Petter Lyngstadaas
-
Publication number: 20160368959Abstract: The embodiments relate to surface-binding peptides having the capability of binding to surfaces of biocompatible materials and can thereby be used to immobilize various heterologous molecules of interest onto the surface. This means that surfaces of, for instance, implants and implantable medical devices can be tailored to present various characteristics by immobilizing selected heterologous molecules of interest on the surfaces of the implants and implantable medical devices. The surface-binding peptides consist of 4-17 consecutive amino acids of an extended beta-hairpin motif EIIATMKKKGEKRCLNP in Interferon gamma-induced protein 10 (IP-10).Type: ApplicationFiled: December 19, 2014Publication date: December 22, 2016Inventors: Lars BRUCE, Staale LYNGSTADAAS
-
Publication number: 20140299548Abstract: A body fluid purifying arrangement comprises a purifying chamber having a fluid input and a fluid output, a first filter arranged in connection the fluid input, and a second filter arranged in connection with the fluid output. In another embodiment, a body fluid purifying arrangement in the form of a syringe comprises a purifying chamber having a common fluid input and fluid output, and a filter arranged in connection with the common fluid input and output. Granules or particles made of a metal or an oxide of a metal are retained within the purifying chamber by the respective filter(s) to purify a body fluid passing through the purifying chamber from 10 kDa interferon-? inducible protein, IP-10, wherein said metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Lars Bruce, Staale Petter Lyngstadaas
-
Publication number: 20140302149Abstract: A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-? inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Lars Bruce, Staale Petter Lyngstadaas
-
Patent number: 8784845Abstract: The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions.Type: GrantFiled: September 11, 2007Date of Patent: July 22, 2014Assignee: Prophy Med ABInventors: Lars Bruce, Staale Petter Lyngstadaas
-
Patent number: 7955613Abstract: A bioartificial implant comprises a semipermeable barrier designed from one side to allow diffusion or prevent diffusion of predetermined substances/materials/molecules/cells/cell lines produced in the human body to the other opposite side of the barrier, and from said other opposite side to allow diffusion or prevent diffusion of predetermined substances which are the same as or different from the first mentioned substances/materials/molecules/cells/cell lines. The semipermeable barrier has a surface coating at least on said one side a bioactive metal, such as titanium, which surface coating is permeable to allow said diffusions. In a method for reducing the risk of formation/growth of connective tissue in connection with an implant which comprises a semipermeable barrier, the barrier is provided at least on one side with a permeable coating of bioactive metal. An example of the use of the implant is bioartificial pancreas.Type: GrantFiled: October 4, 2004Date of Patent: June 7, 2011Assignee: Tikomed ABInventors: Adam Bruce, Lars Bruce, Bo Nilsson, Olle Korsgren
-
Publication number: 20100203089Abstract: The present invention teaches the use of a metal or an oxide of a metal having a capability of reducing the amount of the chemokine IP-IO in a sample and/or reducing the production of IP-IO in cells. The metal is a metal of group 4 or 5 in the periodic table of the elements and preferably titanium. These metals and metal oxides can selectively bind IP-IO to its surface to thereby scavenge IP-IO from the surrounding medium. In addition, a metal-cell contact induces a reduction in the production of IP-IO from IP-IO producing cells. The metals and metal oxides of the present invention can therefore be used for treating and/or preventing medical conditions characterized by adverse IP-IO expression, such as inflammatory reactions.Type: ApplicationFiled: September 11, 2007Publication date: August 12, 2010Applicant: PROPHY MED ABInventors: Lars Bruce, Staale Petter Lyngstadaas
-
Publication number: 20100121446Abstract: A implant assembly (1) includes a frame structure (10) with an inwardly protruding support flange (16), a first frame portion (12) extending above the flange (16) and a second frame portion (14) extending below the flange (16). A first semipermeable membrane (20) is positioned on a first side of the flange (16) and a second membrane (30) is positioned on a second opposite flange side. A first seal (2) is formed at the first frame portion (12) and a second seal (3) is formed at the second frame portion (14) to form an enclosed inner chamber (18) defined by the membranes (20, 30) and the frame structure (10).Type: ApplicationFiled: February 18, 2008Publication date: May 13, 2010Applicant: TICAPEX ABInventors: Lars Bruce, Billy Nilson
-
Publication number: 20090252702Abstract: The present invention relates to the use of amphiphilic block copolymers for treating and preventing cancer, and in particular by reducing the proliferation rate of cancer cells. Preferred block copolymers comprises a central hydrophobic chain, preferably a polypropylene oxide chain, two which at least two hydrophilic side chains, preferably polyethylene oxide chains, are connected.Type: ApplicationFiled: April 23, 2007Publication date: October 8, 2009Applicant: BRUCE MEDICAL ABInventors: Lars Bruce, Ingrid Bruce
-
Patent number: 7553539Abstract: The present invention relates to an irregularly shaped grain for providing ingrowth and growth of connective tissue as well as growth of other cell types leading to cluster of cells, tissues and parts of organs. Said grain includes multiple pores that are continuous through said grain, and openings of said multiple pores and ducts or passages interconnecting at least a portion of said multiple pores have a width of greater than about 10 ?m. Said grain is preferably a metal or metal alloy. The invention also relates to different applications of the grains.Type: GrantFiled: May 2, 2006Date of Patent: June 30, 2009Assignee: Tigran Technologies ABInventors: Ingrid Bruce, Lars Bruce, Adam Bruce
-
Publication number: 20080188857Abstract: In a method and a device for improving the fixing of an elongate prosthesis in a bone cavity, said fixing being provided by a bed in which the prosthesis has been driven down by vibration, a ring of a flexible, essentially plastic material is arranged around the proximal part of the prosthesis so that the ring fills the space between the bone wall and the prosthesis, whereupon the ring is compacted and compressed, after which strokes are made on the prosthesis in its longitudinal direction for final fixing thereof in the bed. The ring significantly improves the strength of the prosthesis in the bed.Type: ApplicationFiled: September 21, 2005Publication date: August 7, 2008Inventors: Lars Bruce, Bengt Mjoberg, Lars Magnus Bjursten
-
Publication number: 20080119944Abstract: A method and an insertion unit for inserting an elongate prosthesis into a prosthesis fixing device. This device comprises a bed of grains and biocompatible material, and a vibrating tool is used for insertion, the vibration head of which performs an oscillating motion back and forth about a swivelling axis (3?). According to the invention, said axis (3r) of the vibrating tool essentially coincides with the longitudinal axis (I1) of the elongate prosthesis (1). The method and the insertion unit provide a prosthesis fixing device consisting of said bed, in which the grains are evenly packed along the length of the prosthesis.Type: ApplicationFiled: September 21, 2005Publication date: May 22, 2008Inventors: Lars Bruce, Bengt Mjoberg, Lars Magnus Bjursten
-
Publication number: 20070003752Abstract: The present invention relates to an irregularly shaped grain for providing ingrowth and growth of connective tissue as well as growth of other cell types leading to cluster of cells, tissues and parts of organs. Said grain includes multiple pores that are continuous through said grain, and openings of said multiple pores and ducts or passages interconnecting at least a portion of said multiple pores have a width of greater than about 10 ?m. Said grain is preferably a metal or metal alloy. The invention also relates to different applications of the grains.Type: ApplicationFiled: May 2, 2006Publication date: January 4, 2007Inventors: Ingrid Bruce, Lars Bruce, Adam Bruce
-
Publication number: 20060263405Abstract: A bioartificial implant comprises a semipermeable barrier designed from one side to allow diffusion or prevent diffusion of predetermined substances/materials/molecules/cells/cell lines produced in the human body to the other opposite side of the barrier, and from said other opposite side to allow diffusion or prevent diffusion of predetermined substances which are the same as or different from the first mentioned substances/materials/molecules/cells/cell lines. The semipermeable barrier has a surface coating at least on said one side a bioactive metal, such as titanium, which surface coating is permeable to allow said diffusions. In a method for reducing the risk of formation/growth of connective tissue in connection with an implant which comprises a semipermeable barrier, the barrier is provided at least on one side with a permeable coating of bioactive metal. An example of the use of the implant is bioartificial pancreas.Type: ApplicationFiled: October 4, 2004Publication date: November 23, 2006Inventors: Adam Bruce, Lars Bruce, Bo Nilsson, Olle Korsgren